Author:
Youssef Eriene A, ,Berry-Kravis Elizabeth,Czech Christian,Hagerman Randi J,Hessl David,Wong Chin Y,Rabbia Michael,Deptula Dennis,John Amy,Kinch Russell,Drewitt Philip,Lindemann Lothar,Marcinowski Moritz,Langland Rachel,Horn Carsten,Fontoura Paulo,Santarelli Luca,Quiroz Jorge A
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Pharmacology
Reference30 articles.
1. Aman MG, Singh NN, Stewart AW, Field CJ (1985). The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89: 485–491.
2. Bear MF, Huber KM, Warren ST (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci 27: 370–377.
3. Berry-Kravis E, Des Portes V, Hagerman R, Jacquemont S, Charles P, Visootsak J et al (2016). Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci Transl Med 8: 321ra325.
4. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK (2013). Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr 34: 508–522.
5. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J et al (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 46: 266–271.
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献